<DOC>
	<DOCNO>NCT02240238</DOCNO>
	<brief_summary>In dose escalation phase ( Part 1 ) , study determine dose-limiting toxicity ( DLTs ) , maximum tolerate dose ( MTD ) recommend Phase 2 ( RPII ) dose NC 6004 combination gemcitabine . In expansion phase study ( Part 2 ) , study evaluate activity , safety , tolerability RPII dose identify Part 1 patient squamous NSCLC , biliary tract , bladder cancer .</brief_summary>
	<brief_title>Combination Therapy With NC-6004 Gemcitabine Advanced Solid Tumors Non-Small Cell Lung , Biliary Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>( Part 1 ) Have histologically cytologically confirm diagnosis advance solid tumor relapse refractory standard curative palliative therapy contraindication standard therapy . ( Part 2 ) Cohort 1 : Have histologically cytologically confirm diagnosis Stage IV squamous NSCLC receive prior chemotherapy immunotherapy metastatic disease know PDL1 positive ( know high PDL1 expression define Tumor Proportion Score [ TPS ] great equal 50 % ) . Patients know sensitize mutation epidermal growth factor receptor ( EGFR ) gene anaplastic lymphoma kinase ( ALK ) fusion oncogene must receive least 1 2 targeted therapy prior enrollment . ( Part 2 ) Cohort 2 : Have histologically cytologically confirm diagnosis nonresectable , recurrent , metastatic biliary tract carcinoma ( intrahepatic extrahepatic cholangiocarcinoma , gallbladder cancer , ampullary carcinoma ) receive prior systemic anticancer therapy advance metastatic disease . ( Part 2 ) Cohort 3 : Have histologically cytologically confirm diagnosis metastatic locally advanced TCC urinary tract ( bladder , urethra , ureter , renal pelvis ) ( T3bT4 N0 M0 , Tany N1N3 M0 , Tany Nany M1 ) candidate surgery . Have measurable disease per RECIST version 1.1 . Have ECOG PS 0 1 , exception patient Part 2 ( Cohort 3 , unfit bladder cancer patient ) may ECOG PS 2 Adequate bone marrow reserve , liver renal function Have negative pregnancy test result Screening female childbearing potential Male patient must agree use condom treatment 90 day dose must agree donate sperm 90 day dose Women childbearing potential willing agree use 1 study define effective method birth control time study entry 6 month last day treatment Reasonably recover precede major surgery judge investigator major surgery within 4 week prior start Day 1 treatment Have receive prior platinum therapy past 3 month ( Part 1 ) 6 month adjuvant neoadjuvant setting ( Part 2 ) . Have receive prior cisplatin gemcitabine concomitantly within last 6 month refractory cisplatin gemcitabine . Unresolved toxicity prior radiation , chemotherapy , target treatment , include investigational treatment Have evidence suggest pulmonary fibrosis interstitial pneumonia . Have history thrombocytopenia complication Have know hypersensitivity platinum compound gemcitabine . Have uncontrolled diabetes hypertension require 3 medication control hypertension . Have preexist alcoholic liver injury significant liver disease . Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>